Johnson & Johnson (JNJ)
144.47
+0.89
(+0.62%)
USD |
NYSE |
Dec 20, 16:00
144.61
+0.14
(+0.10%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 347.83B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -3.52% |
| Valuation | |
| PE Ratio | 23.88 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.000 |
| Price to Book Value | 4.958 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.24 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5096 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.36% |
Profile
| Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States. |
| URL | https://www.jnj.com |
| Investor Relations URL | https://www.investor.jnj.com |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 22, 2025 |
| Last Earnings Release | Oct. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 27, 2024 |
Ratings
Profile
| Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States. |
| URL | https://www.jnj.com |
| Investor Relations URL | https://www.investor.jnj.com |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 22, 2025 |
| Last Earnings Release | Oct. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 27, 2024 |